Meropenem Ligula Pharma (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins. This blocks the final cross‑linking step of peptidoglycan formation, causing cell‑wall weakening, osmotic lysis, and bacterial death. Its stability against many β‑lactamases expands its activity to resistant strains.

The exact dosage is determined by the prescribing clinician based on infection severity, site, pathogen susceptibility, patient weight, and renal function. Dosing regimens are individualized and should follow local guidelines or the product’s prescribing information.

Safety data for Meropenem in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Meropenem offers a broad spectrum similar to other carbapenems like imipenem‑cilastatin and ertapenem, but it has enhanced activity against certain resistant Gram‑negative organisms, including Pseudomonas aeruginosa. Compared with non‑carbapenem β‑lactams, it is less affected by most β‑lactamases, making it a preferred option for multidrug‑resistant infections.

Meropenem Ligula Pharma should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect from light, and avoid freezing or shaking. Once reconstituted, use according to the manufacturer’s stability guidelines.

The product is supplied as a sterile powder for injection. It must be reconstituted with the appropriate diluent and administered intravenously, typically as a short infusion over 15‑30 minutes. Administration should be performed by qualified healthcare personnel in a clinical setting.

Serious adverse events include seizures (especially in patients with renal impairment or pre‑existing CNS disorders), severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and hepatotoxicity. Prompt recognition and medical intervention are essential if these occur.

Meropenem is contraindicated in patients with a known hypersensitivity to carbapenems or any β‑lactam antibiotics. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving valproic acid, as interactions may increase risk.